Dr Reddys Laboratories has settled patent litigation with Indivior Inc and Aquestive Therapeutics on a medication used to treat opioid dependence or addiction. A US Court dismissed all claims and counterclaims pending in the case with prejudice, pursuant to a joint stipulation of dismissal filed by the parties, the Hyderabad-based drug major said in a statement.
"The settlement and dismissal resolve all claims between the parties, including Indivior's and Aquestive's claims for patent infringement as well as the company's antitrust counterclaim against Indivior," Dr Reddy's said.
Dr Reddy's Lab has entered into a settlement agreement with Indivior Inc and Aquestive Therapeutics as a result of which it will receive payments totalling USD 72 million by March 31, 2024.
The said agreement resolves all claims between the parties relating to the company's generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, it had said.
Buprenorphine and naloxone sublingual film medication is used to treat opioid dependence or addiction.
Subscribe to PharmaTutor News Alerts by Email
